Selinexor Maintenance Therapy for Endometrial Cancer
(ENGOT-EN5 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a prospective, multicenter, double-blind, placebo-controlled, randomized Phase 3 study. The purpose of the study is to obtain evidence of efficacy for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recurrent disease who are in partial or complete response after having completed a single line of at least 12 weeks of taxane-platinum combo therapy will be randomized in a 2:1 manner to maintenance therapy with 80 milligram (mg) with selinexor once weekly (QW) or placebo until progression.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, you cannot be on any concurrent cancer therapy or investigational agents during the trial.
Is Selinexor safe for humans?
How is the drug selinexor unique for treating endometrial cancer?
Selinexor is unique because it works by inhibiting exportin-1 (XPO1), which leads to the accumulation of tumor suppressor proteins like p53 in the cell nucleus, helping to control cancer growth. It is taken orally once a week and has shown significant benefits in delaying the progression of advanced or recurrent endometrial cancer, especially in patients with TP53 wild-type tumors.12467
What data supports the effectiveness of the drug Selinexor for endometrial cancer?
Who Is on the Research Team?
Michael Kauffman, MD, PhD
Principal Investigator
Karyopharm Therapeutics Inc
Are You a Good Fit for This Trial?
This trial is for women aged 18+ with advanced or recurrent endometrial cancer who've responded to taxane-platinum chemotherapy. They must have good performance status, adequate organ function, and not be pregnant or breastfeeding. Exclusions include previous treatment with certain inhibitors or immunotherapies, recent transfusions, major surgeries, other active cancers (except some skin cancers), uncontrolled infections, and inability to swallow tablets.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive maintenance therapy with selinexor or placebo once weekly until progression
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Matching placebo for Selinexor
- Selinexor
Find a Clinic Near You
Who Is Running the Clinical Trial?
Karyopharm Therapeutics Inc
Lead Sponsor
Richard Paulson
Karyopharm Therapeutics Inc
Chief Executive Officer since 2021
MBA from the University of Toronto's Rotman School of Management
Reshma Rangwala
Karyopharm Therapeutics Inc
Chief Medical Officer since 2023
MD, PhD
Israeli Society of Gynecologic Oncology
Collaborator
GOG Foundation
Collaborator
Belgian Gynaecological Oncology Group
Collaborator
Spanish Research Group in Ovarian Cancer
Collaborator
The Central and Eastern European Gynecologic Oncology Group
Collaborator
Israel Society of Gynecologic Oncology
Collaborator
The GOG Foundation, Inc.
Collaborator
Belgium and Luxembourg Gynaecological Oncology Group
Collaborator
North-Eastern German Society of Gynaecologic Oncology
Collaborator